Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031317 | 0.88 | CYP17A1 (0.36) | SLC5A1SLC5A2P2RX3KCNH2TMEM97 | |
| SCHEMBL10064334 | 0.85 | PDE1A (0.38) | SLC5A1SLC5A2DAOP2RX3P2RX7 | |
| SCHEMBL10031310 | 0.79 | SLC5A1 (0.56) | SLC5A1SLC5A2P2RX3LMNA | |
| SCHEMBL14285952 | 0.75 | SLC5A1 (0.43) | SLC5A1SLC5A2P2RX3 | |
| SCHEMBL14626488 | 0.74 | SLC5A1 (0.45) | SLC5A1SLC5A2KCNH2TMEM97SIGMAR1 | |
| SCHEMBL2047708 | 0.73 | SLC5A2 (0.72) | SLC5A1SLC5A2 | |
| SCHEMBL3772111 | 0.73 | SLC5A2 (0.72) | SLC5A1SLC5A2 | |
| SCHEMBL10064335 | 0.73 | CHRM4 (0.38) | SLC5A1SLC5A2P2RX7 | |
| SCHEMBL3772106 | 0.72 | SLC5A2 (0.49) | SLC5A1SLC5A2 | |
| SCHEMBL14285953 | 0.72 | SLC5A2 (0.41) | SLC5A1SLC5A2P2RX3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053330-A1 | Chemical Process | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053330-A1 | Chemical Process | SLC5A2, SLC5A1, UGGT1 | SLC5A1 2/4885SLC5A2 1/4885DAO 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.